LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to ...
AstraZeneca will pay $1.2 billion upfront to CSPC for eight obesity candidates, with milestone payments potentially lifting the deal to $18.5 billion.
Pharmaceutical Technology on MSN
AstraZeneca signs $18.5bn weight loss drug deal with CSPC
AstraZeneca has returned to CSPC with a licensing deal for the Chinese company’s monthly injectables for obesity.
The agreement, to gain rights to a portfolio of early-stage experimental obesity and diabetes drugs is the largest of its ...
Add Yahoo as a preferred source to see more of our stories on Google. President Donald Trump participates in a bilateral meeting with Finland's President Alexander Stubb, in the Oval Office of the ...
Pharmaceutical giant Pfizer has been circling its smaller rival for months. AstraZeneca has rejected every offer saying Pfizer undervalues the... Pfizer Drops $119 Billion Bid For AstraZeneca It would ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results